AbbVie completed acquisition of Allergan for nearly $62 billion
On May 8, 2020, AbbVie announced it had completed its acquisition of Allergan following receipt of regulatory approval…
-
-
Entos Pharma partnered with Precision NanoSystems to enable scalable GMP manufacturing of Fusogenix DNA COVID-19 vaccine
On May 7, 2020, Entos Pharmaceuticals announced a partnership with Precision NanoSystems, Inc., (PNI), a global leader in…
-
Mesoblast announced first patients dosed in phase 2/3 trial for COVID-19 ARDS
On May 6, 2020, Mesoblast announced that the first patients were dosed in the 300-patient randomized placebo-controlled Phase…
-
Laurent Pharmaceuticals received Health Canada’s approval to initiate COVID-19 clinical trial
On May 6, 2020, Laurent Pharmaceuticals announced that it has obtained the approval from Health Canada to initiate…
-
Biotechnology | COVID-19 | Diagnostics | Medical Device | Non-Profit Research | Pharmaceutical | Therapeutics
USPTO launched platform to facilitate connections between patent holders and potential licensees in key technologies
On May 4, 2020, the U.S. Patent and Trademark Office (USPTO) unveiled a new web-based intellectual property marketplace…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Non-Profit Research | Pharmaceutical | Therapeutics
Government of Canada Investing in global race to find a treatment for COVID-19
On May 3, 2020, the Government of Canada announced it was investing in projects that support the global…
-
Mesoblast began enrollment in phase 2/3 clinical trial of remestemcel-L in 300 patients with acute respiratory distress syndrome
On Apr. 30, 2020, Mesoblast announced a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether its allogeneic…
-
Mateon announced peer reviewed publication on its R&D effort against COVID-19
On Apr. 30, 2020, Mateon Therapeutics report several peer-reviewed publications derived from its R&D effort against COVID-19. Published April…
-
Entos Pharmaceuticals partnered with EpiVax to develop a pan-Coronavirus DNA vaccine
On Apr. 28, 2020, Entos Pharmaceuticals announced a collaboration with EpiVax, a world leading informatics and immunology biotechnology…
-
Phase 3 trial of Libtayo (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival
On Apr. 27, 2020, Regeneron and Sanofi announced the primary endpoint of overall survival was met in a…
-
Mesoblast reported 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome
On Apr. 24, 2020, Mesoblast announced an 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory…
-
Emergent BioSolutions signed agreement to be U.S. manufacturing partner for Johnson & Johnson’s lead vaccine candidate for COVID-19
On Apr. 23, 2020, Emergent BioSolutions announced an agreement whereby Emergent will deploy its contract development and manufacturing…
-
Cocrystal Pharma expanded exclusive license agreement with Kansas State University Research Foundation to new Coronavirus antiviral compound
On Apr. 22, 2020, Cocrystal Pharma announced it has expanded its previously announced license agreement with Kansas State…
-
Biology | Diagnostics | Infectious Disease | Life Science History | Medicine | Pharmaceutical | Radiology | Therapeutics | U.S. Congress | Vaccine
The US Veterans Affairs established the department’s first history office
On Apr. 10, 2020, the U.S. Department of Veterans Affairs (VA) established the VA History Office (VAHO) to…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Medicine | Pharmaceutical | Therapeutics
Data on 53 patients treated with investigational antiviral remdesivir through Compassionate Use Program published in NEJM
On Apr. 10, 2020, Gilead Sciences announced results from a cohort analysis of 53 patients hospitalized with severe…
-
Biotechnology | COVID-19 | Infectious Disease | Influenza | Medicine | Pharmaceutical | Therapeutics
Fujifilm announced the start of a phase II clinical trial of its influenza antiviral drug ‘Avigan’ Tablet for COVID-19 patients in the U.S.
On Apr. 9, 2020, FUJIFILM announced initiation of a U.S. phase II clinical trial to evaluate the safety…
-
Chugai started phase III clinical trial of Actemra for COVID-19 pneumonia in Japan
On Apr. 8, 2020, Chugai Pharma announced that it is working to start a phase III clinical trial…
-
COVID-19 will likely lead to US drug shortages
On Mar. 27, 2020, researchers at the University of Minnesota reported that the COVID-19 pandemic stands a good…
-
Artificial Intelligence | Biotechnology | COVID-19 | Infectious Disease | Life Science History | Non-Profit Research | Pharmaceutical | Therapeutics
COVID-19 first target of new AI research consortium
On Mar. 26, 2020, the University of California, Berkeley, and University of Illinois at Urbana-Champaign were selected a…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Medical Device | Non-Profit Research | Pharmaceutical | Therapeutics | WHO
WHO Director-General calls on G20 to fight, unite, and ignite against COVID-19
On Mar. 26, 2020, Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), addressed Heads of…
-
Patients with severe Coronavirus disease could offer clues to treatment
On Mar. 24, 2020, an international project aimed to enroll 500 COVID-19 patients to search for genetic mutations…
-
Biotechnology | COVID-19 | Infectious Disease | Non-Profit Research | Pharmaceutical | Therapeutics | Vaccine
Oxford University’s COVID-19 research received government funding
On Mar. 24, 2020, three Oxford University-based COVID-19 projects were among the first to benefit from a share…
-
Biotechnology | COVID-19 | Diagnostics | Disease | Infectious Disease | Pharmaceutical | Therapeutics
BioSig subsidiary NeuroClear acquired license for a broad-spectrum anti-viral agent that may treat COVID-19
On Mar. 24, 2020, BioSig Technologies announced that its majority-owned subsidiary NeuroClear Technologies, acquired the rights to develop a…
-
Biotechnology | Diagnostics | Medicine | NIH | Non-Profit Research | Oncology | Pharmaceutical | Radiology | Therapeutics
The Simmons Cancer Center joined elite National Comprehensive Cancer Network
On Mar. 24, 2020, the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern announced it had joined…
-
COVID-19 pandemic drove accelerated demand for Covetrus online pharmacy services
On Mar. 23, 2020, Covetrus reported that the company saw strong demand in its prescription management and online…
-
Artificial Intelligence | Biotechnology | COVID-19 | FDA | Infectious Disease | Oncology | Pharmaceutical | Therapeutics
Mateon to develop its OT-101, a phase 3 clinical drug candidate against COVID-19
On Mar. 18, 2020, Mateon Therapeutics reported significant progress in deploying its phase 3 clinical asset, OT-101, against…
-
Innovation Pharmaceuticals Brilacidin tested as drug and vaccine at different institutions
On Mar. 17, 2020, Innovation Pharma announced details on the Material Transfer Agreement signed with a leading public…
-
Enanta Pharmaceuticals announced efforts to discover treatment for novel Coronavirus disease
On Mar. 13, 2020, Enanta Pharmaceuticals announced it had initiated a program to discover direct-acting antiviral drug candidates…
-
Biotechnology | Disease | FDA | Neurology | Pharmaceutical | Therapeutics
FDA approved Lundbeck’s VYEPTI™ – the first and only intravenous preventive treatment for migraine
On Feb. 21, 2020, Lundbeck announced that VYEPTI™ (eptinezumab-jjmr) had been approved by the U.S. Food and Drug…
-
BioMotiv and Bristol-Myers Squibb announced the Launch of Anteros Pharmaceuticals
On Feb. 4, 2020, BioMotiv and Bristol-Myers Squibb announced the launch of Anteros Pharmaceuticals, a biotechnology company focused…
